T.Muris

Technology

• Increasing evidence confirms that the gut microbiota is involved in a number of diseases, particularly in the development of obesity and related disorders.
• Turicimonas muris (T. muris) is a proteobacterium derived from the human gut microbiota.
• A negative correlation has been observed between the abundance of T. muris in the body and body weight.
• Using T. muris as a probiotic could help improve and prevent metabolic disturbances and weight gain in individuals with obesity.
• It may be administered alone or in combination with other bacteria or drugs intended for treatment.
• Additionally, T. muris could be used as an adjuvant in diabetes therapies or as a complement to bariatric surgery.

Market

• Today, nearly 50% of the European population and 17% of the French population are overweight or obese.
• However, available drug treatments for obesity remain limited and are mostly reserved for severe cases, despite the substantial costs associated with managing affected individuals.
• To prevent these conditions, control their progression, and reduce the significant costs of treatment, it is essential to develop non-invasive, more effective, and more affordable solutions.

Development status

• Proof of concept demonstrated in vivo: In mice fed a high-fat diet, administration of a small amount of the bacteria in parallel yielded the following results:
  • After 3 weeks, fasting blood sugar levels in mice that received the bacteria decreased by 40% compared to those that did not receive it;
  • After 12 weeks, body mass in mice receiving the bacteria was reduced by 12% compared to those that did not receive it.

IP

• A PCT patent application WO2024/133647, with a priority filing date of 2022/12/22.
• This application has entered the national phase in EU, CA, US, JP, KR, MX.

Valorisation strategy

• Startup